CymaBay Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

CymaBay Therapeutics kazanç ve gelirin sırasıyla yıllık 54.8% ve 50.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 54.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -50.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

54.8%

Kazanç büyüme oranı

54.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.6%
Gelir büyüme oranı	50.9%
Gelecekteki özkaynak getirisi	-50.1%
Analist kapsamı	Good
Son güncelleme	29 Feb 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:CBAY - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	274	-46	11	21	7
12/31/2025	115	-158	-97	-116	8
12/31/2024	2	-175	-181	-160	4
12/31/2023	31	-105	-73	-73	N/A
9/30/2023	31	-90	-64	-64	N/A
6/30/2023	31	-81	-56	-55	N/A
3/31/2023	N/A	-107	-53	-52	N/A
12/31/2022	N/A	-106	-84	-84	N/A
9/30/2022	N/A	-106	-80	-80	N/A
6/30/2022	N/A	-104	-78	-77	N/A
3/31/2022	N/A	-100	-74	-74	N/A
12/31/2021	N/A	-90	-70	-69	N/A
9/30/2021	N/A	-79	-70	-70	N/A
6/30/2021	N/A	-68	-62	-62	N/A
3/31/2021	N/A	-55	-51	-51	N/A
12/31/2020	N/A	-51	-45	-45	N/A
9/30/2020	N/A	-65	-58	-58	N/A
6/30/2020	N/A	-80	-74	-74	N/A
3/31/2020	N/A	-93	-90	-90	N/A
12/31/2019	N/A	-103	-98	-98	N/A
9/30/2019	N/A	-93	-90	-89	N/A
6/30/2019	N/A	-85	-83	-82	N/A
3/31/2019	N/A	-79	-72	-71	N/A
12/31/2018	N/A	-73	-55	-55	N/A
9/30/2018	5	-58	-41	-41	N/A
6/30/2018	5	-48	-31	-31	N/A
3/31/2018	5	-39	-24	-24	N/A
12/31/2017	10	-28	-20	-20	N/A
9/30/2017	5	-29	N/A	-19	N/A
6/30/2017	5	-27	N/A	-19	N/A
3/31/2017	5	-25	N/A	-19	N/A
12/31/2016	N/A	-27	N/A	-23	N/A
9/30/2016	N/A	-26	N/A	-23	N/A
6/30/2016	N/A	-26	N/A	-24	N/A
3/31/2016	N/A	-20	N/A	-23	N/A
12/31/2015	N/A	-16	N/A	-23	N/A
9/30/2015	N/A	-22	N/A	-26	N/A
6/30/2015	N/A	-22	N/A	-23	N/A
3/31/2015	N/A	-24	N/A	-22	N/A
12/31/2014	N/A	-32	N/A	-21	N/A
9/30/2014	N/A	208	N/A	-17	N/A
6/30/2014	N/A	257	N/A	-14	N/A
3/31/2014	N/A	240	N/A	-11	N/A
12/31/2013	N/A	244	N/A	-8	N/A
9/30/2013	0	11	N/A	-5	N/A
6/30/2013	3	-36	N/A	-8	N/A
3/31/2013	3	-23	N/A	-10	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CBAY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: CBAY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: CBAY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: CBAY şirketinin gelirinin (yıllık 50.9% ) US pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CBAY şirketinin gelirinin (yıllık 50.9% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CBAY 3 yıl içinde kârsız olması bekleniyor.

CymaBay Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Price target increased by 8.5% to US$31.07

Forecast to breakeven in 2026

Price target increased by 7.5% to US$24.82

Price target increased by 17% to US$21.27

Consensus revenue estimates increase by 156%

Recent updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Price target increased by 8.5% to US$31.07

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

Forecast to breakeven in 2026

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

Cymabay Therapeutics, Inc. Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

Price target increased by 7.5% to US$24.82

New minor risk - Profitability

CymaBay Therapeutics, Inc. Announces Publication of Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President exercised options and sold US$597k worth of stock

General Counsel notifies of intention to sell stock

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999939 million.

Price target increased by 17% to US$21.27

Insider notifies of intention to sell stock

Consensus revenue estimates increase by 156%

Price target increased by 8.0% to US$17.64

New minor risk - Profitability

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates fall by 15%

Price target increased by 8.5% to US$15.56

Insider notifies of intention to sell stock

Price target increased by 8.2% to US$14.67

New minor risk - Share price stability

Insider notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Consensus revenue estimates fall by 40%

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. Appoints Harish Shantharam as Chief Financial Officer

Executive Officer notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Price target increased by 11% to US$13.56

Price target increased by 8.1% to US$11.63

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999785 million.

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Cymabay Completes Enrollment for the Response Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from Russell 2000 Dynamic Index

CymaBay Therapeutics, Inc. Presents Positive PBC Data at the International Liver Congress 2022

President recently bought US$100k worth of stock

CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Price target decreased to US$10.50

Insufficient new directors

CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nominating and Corporate Governance Committee of the Board

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?

Chief Medical Officer recently bought US$61k worth of stock

Why I've Taken A 'Starter' Position In CymaBay Therapeutics

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Cymabay Therapeutics, Inc. Announces Positive Data from Its Previously Completed Phase 2 Study and the Enhance Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis

We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

Independent Director has left the company

Price target decreased to US$12.00

CymaBay Therapeutics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

New 90-day low: US$5.32

We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely